SUN PHARMA

PRESENTED TO:
MR. NIYAT SHETTY

PRESENTED BY:
MEHAR PARKAR
LAVITA COELHO
KALPIT BHAGAT

INTRODUCTION

Sun Pharmaceuticals was established by Mr. Dilip Shanghvi in 1983

in Kolkata with five products to treat psychiatry ailments.

Over 57% of Sun Parma sales are from markets outside India,
primarily in the US.

Manufacturing is across 23 locations, including the US, Canada,

Brazil, Mexico and Israel.

In the US, the company markets over 200 generics, with another 150
awaiting approval from the U.S. Food and Drug Administration.

Sun Parma was listed on the stock exchange in 1994 in an issue

oversubscribed 55 times

INTRODUCTION

The founding family continues to hold a majority stake in the

company.

A large part of Sun Pharmas growth can be attributed to a

number of key acquisitions over the last two decades.

Today it is the largest chronic prescription company in India and a

market leader in psychiatry, neurology, cardiology, orthopedics,
ophthalmology, gastroenterology and nephrology

Today Sun Pharma is the third largest and the most profitable
pharmaceutical company in India as well as the largest
pharmaceutical company by market capitalisation on the Indian
exchanges.

Problems faced by sun

pharmaceuticals limited
PROBLEMS

LOSSES FACED

Patent dispute settlement.

Launch of generic copies
of Wyeths patented acid
reflex brand Protonix.
Civil and criminal charges
related to manufacturing
compliance issues.

$550 million (around

Rs.3,190 crore) Pfizer Inc.
Teva Pharmaceutical
Industries Ltd fighting in a
New Jersey court a patent
infringement petition filed by
Wyeth Inc, part of Pfizer.
Paid a fine of $550 million US Food and Drug
Administration.

OTHER ISSUES

The company was in the midst of the

damages phase of a jury trial in a
federal court in Newark.
The court ruled in favor of Pfizer in
the case
Sun Pharma and Teva launched their
generic versions of the pantoprazole
drug in the US in 2008.
As part of the settlement, both Teva
and Sun have admitted that their sales
of generic pantoprazole infringed the
patent that was held valid by the court
Pfizer wanted roughly $3 billion in
damages, based on its sales of Protonix
before the generic competition began
in 2007, and it wanted Sun Pharma to
pay $960 million.

SOLUTIONS

First of all the manufacturer should have checked the

patent and then should have passed the patent of the
medicine.
Because it was the biggest mistake made here by the
manufacturer and was heavily repaid by the company in
the court.
The mistake caused them a deep fall in their share price
(from rs.981 to less than rs.700)
This deep fall caused a deep panic in the minds of share
holder.
But now the company is doing well and slowly and
steadily coming on track.